Table 1.
Demographic and clinical data of the study patients.
| Group | ||||
|---|---|---|---|---|
| Total (N = 853) |
None (n = 569) |
Metastasis (n = 284) |
P value | |
| n (%) or median (min–max) | n (%) or median (min–max) | n (%) or median (min–max) | ||
| Age (years) | 52 (22–88) | 53 (22–88) | 52 (25–86) | .383 |
| Sex | 1.000 | |||
| Male | 2 (0.2) | 1 (0.2) | 1 (0.4) | |
| Female | 851 (99.8) | 568 (99.8) | 283 (99.6) | |
| Tumoral type | <.001 | |||
| Non-special type of invasive carcinoma | 701 (82.2) | 449 (78.9) | 252 (88.7) | |
| Other | 152 (17.8) | 120 (21.1) | 32 (11.3) | |
| Receptor group | .364 | |||
| ER and/or PR (+), HER2 (−) | 453 (53.1) | 312 (54.8) | 141 (49.6) | .153 |
| ER and/or PR (+), HER2 (+) | 247 (29) | 159 (27.9) | 88 (31) | .356 |
| ER (−), PR (−), HER2 (−) | 86 (10.1) | 52 (9.1) | 34 (12) | .195 |
| ER (−), PR (−), HER2 (+) | 67 (7.9) | 46 (8.1) | 21 (7.4) | .827 |
| HER2 | .502 | |||
| Negative | 539 (63.2) | 364 (64) | 175 (61.6) | |
| Positive | 314 (36.8) | 205 (36) | 109 (38.4) | |
| ER | .148 | |||
| Negative | 177 (20.8) | 110 (19.3) | 67 (23.6) | |
| Positive | 676 (79.2) | 459 (80.7) | 217 (76.4) | |
| PR | .210 | |||
| Negative | 241 (28.3) | 153 (26.9) | 88 (31) | |
| Positive | 612 (71.7) | 416 (73.1) | 196 (69) | |
| Ki67 | .277 | |||
| Negative | 294 (34.5) | 189 (33.2) | 105 (37) | |
| Positive | 559 (65.5) | 380 (66.8) | 179 (63) | |